Complement inhibition significantly decreases red blood cell lysis in a rat model of acute intravascular hemolysis

Transfusion

Volumn 54, Issue 11, 2014, Pages 2892-2900

  Shah, Tushar A ^a,b,c   Mauriello, Clifford T ^a   Hair, Pamela S ^a   Sharp, Julia A ^a   Kumar, Parvathi S ^a   Lattanzio, Frank A ^a   Werner, Alice L ^a,b,c   Whitley, Pamela H ^d   Maes, Lou Ann ^d   Cunnion, Kenji M ^a,b,c   Krishna, Neel K ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b Children's Specialty Group   (United States)

^c CHILDREN S HOSPITAL OF THE KING S DAUGHTERS   (United States)

^d AMERICAN RED CROSS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COBROTOXIN; COMPLEMENT; HEMOGLOBIN; COMPLEMENT INHIBITOR; SNAKE VENOM;

ACUTE DISEASE; ACUTE INTRAVASCULAR HEMOLYSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT INHIBITION; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; FLOW CYTOMETRY; HEMOLYSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTRAVASCULAR HEMOLYSIS; MALE; NONHUMAN; PLASMA CLEARANCE; PROTEIN FUNCTION; RAT; SPECTROPHOTOMETRY; TITRIMETRY; VASCULAR ACCESS; ANIMAL; DISEASE MODEL; DRUG EFFECTS; ERYTHROCYTE; LIVER; METABOLISM; MOUSE; PATHOLOGY; SPECIES DIFFERENCE; SPLEEN; WISTAR RAT;

ACUTE DISEASE; ANIMALS; COBRA VENOMS; COMPLEMENT INACTIVATING AGENTS; COMPLEMENT PATHWAY, CLASSICAL; COMPLEMENT SYSTEM PROTEINS; DISEASE MODELS, ANIMAL; ERYTHROCYTE TRANSFUSION; ERYTHROCYTES; HEMOLYSIS; HUMANS; LIVER; MICE; RATS; RATS, WISTAR; SPECIES SPECIFICITY; SPLEEN;

EID: 84912116585     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12695     Document Type: Article

References (20)

1. Refaai MA, Blumberg N,. The transfusion dilemma-weighing the known and newly proposed risks of blood transfusions against the uncertain benefits. Best Pract Res Clin Anaesthesiol 2013; 27: 17-35.
2. Davenport RD,. Hemolytic transfusion reactions Rossi's principles of transfusion medicine. Hoboken (NJ): Wiley Blackwell; 2009. p. 811-825.
3. Bolton-Maggs PH, Cohen H,. Serious Hazards of Transfusion (SHOT) haemovigilance and progress is improving transfusion safety. Br J Haematol 2013; 163: 303-314.
4. Engelfriet CP,. The immune destruction of red cells. Transfus Med 1992; 2: 1-6.
5. Win N, Sinha S, Lee E, et al. Treatment with intravenous immunoglobulin and steroids may correct severe anemia in hyperhemolytic transfusion reactions: case report and literature review. Transfus Med Rev 2010; 24: 64-67.
6. Strobel E,. Hemolytic transfusion reactions. Transfus Med Hemother 2008; 35: 346-353.
7. Stowell SR, Winkler AM, Maier CL, et al. Initiation and regulation of complement during hemolytic transfusion reactions. Clin Dev Immunol 2012; 2012: 307093.
8. Yazdanbakhsh K, Kang S, Tamasauskas D, et al. Complement receptor 1 inhibitors for prevention of immune-mediated red cell destruction: potential use in transfusion therapy. Blood 2003; 101: 5046-5052.
9. Schirmer DA, Song SC, Baliff JP, et al. Mouse models of IgG- and IgM-mediated hemolysis. Blood 2007; 109: 3099-3107.
10. Hod EA, Arinsburg SA, Francis RO, et al. Use of mouse models to study the mechanisms and consequences of RBC clearance. Vox Sang 2010; 99: 99-111.
11. Gronemus JQ, Hair PS, Crawford KB, et al. Potent inhibition of the classical pathway of complement by a novel C1q-binding peptide derived from the human astrovirus coat protein. Mol Immunol 2010; 48: 305-313.
12. Mauriello CT, Pallera HK, Sharp JA, et al. A novel peptide inhibitor of classical and lectin complement activation including ABO incompatibility. Mol Immunol 2013; 53: 132-139.
13. Morgan BP, Harris CL,. Complement therapeutics; history and current progress. Mol Immunol 2003; 40: 159-170.
14. Wu X, Spitzer D, Mao D, et al. Membrane protein Crry maintains homeostasis of the complement system. J Immunol 2008; 181: 2732-2740.
15. Jacobson AC, Weis JH,. Comparative functional evolution of human and mouse CR1 and CR2. J Immunol 2008; 181: 2953-2959.
16. Molina H, Wong W, Kinoshita T, et al. Distinct receptor and regulatory properties of recombinant mouse complement receptor 1 (CR1) and Crry, the two genetic homologues of human CR1. J Exp Med 1992; 175: 121-129.
17. Tanaka S, Suzuki T, Nishioka K,. Assay of classical and alternative pathway activities of murine complement using antibody-sensitized rabbit erythrocytes. J Immunol Methods 1986; 86: 161-170.
18. Aptekman PM, Bogden AE,. Characterization of the natural hemagglutinins in normal rat serum associated with a negative phase following tumor implantation. Cancer Res 1956; 16: 216-221.
19. Wright MC, Nelson RA Jr, Finch SC,. The effects of a cobra venom factor and ethyl palmitate on the prolongation of survival of heterologous erythrocytes. Yale J Biol Med 1970; 43: 173-176.
20. Wouters D, Stephan F, Strengers P, et al. C1-esterase inhibitor concentrate rescues erythrocytes from complement-mediated destruction in autoimmune hemolytic anemia. Blood 2013; 121: 1242-1244.